Arcturus Therapeutics(ARCT)
$9.31-0.08 (-0.85%)
ARCT
Arcturus Therapeutics financials statements
$9.31
At close:-0.08 (-0.85%)
Want to see ARCT full AI Analyst Report?
Arcturus Therapeutics (ARCT) Ratios
2,164 Followers
Arcturus Therapeutics Ratios
ARCT's free cash flow for Q3 2026 was $-6.96M. For the 2026 fiscal year, ARCT's free cash flow was decreased by $-52.00K and operating cash flow was $-6.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 |
| Quick Ratio | 6.64 | 4.67 | 4.72 | 3.18 | 3.81 |
| Cash Ratio | 6.35 | 3.62 | 3.56 | 3.09 | 3.72 |
| Solvency Ratio | -1.10 | -0.75 | -0.18 | 0.06 | -1.23 |
| Operating Cash Flow Ratio | -2.04 | -0.91 | -0.22 | 0.25 | -1.36 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.53 | -6.01 |
| Net Current Asset Value | $ 184.28M | $ 202.89M | $ 235.70M | $ 223.26M | $ 214.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.08 | 0.07 | 0.21 | 0.18 |
| Debt-to-Equity Ratio | 0.12 | 0.12 | 0.11 | 0.35 | 0.30 |
| Debt-to-Capital Ratio | 0.10 | 0.11 | 0.10 | 0.26 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 |
| Financial Leverage Ratio | 1.27 | 1.43 | 1.54 | 1.67 | 1.72 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -33.90 | 0.19 | -8.02 |
| Interest Coverage Ratio | 0.00 | 0.00 | -101.96 | 4.06 | -75.86 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.14 | 0.06 |
| Interest Debt Per Share | 0.91 | 1.06 | 1.16 | 3.70 | 2.73 |
| Net Debt to EBITDA | 3.28 | 2.69 | 10.83 | -21.68 | 1.49 |
| Profitability Margins | |||||
| Gross Profit Margin | 95.50% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -97.86% | -58.49% | -17.19% | 5.92% | -1641.33% |
| EBITDA Margin | -93.36% | -55.93% | -15.32% | 6.66% | -1631.68% |
| Operating Profit Margin | -111.51% | -69.13% | -49.58% | 5.92% | -1641.33% |
| Pretax Profit Margin | -97.86% | -58.49% | -17.68% | 5.17% | -1647.98% |
| Net Profit Margin | -97.86% | -58.49% | -18.84% | 4.54% | -1647.98% |
| Continuous Operations Profit Margin | -97.86% | -58.49% | -18.84% | 4.54% | -1647.98% |
| Net Income Per EBT | 100.00% | 100.00% | 106.58% | 87.83% | 100.00% |
| EBT Per EBIT | 87.76% | 84.61% | 35.66% | 87.41% | 100.41% |
| Return on Assets (ROA) | -24.26% | -23.52% | -6.92% | 2.08% | -51.85% |
| Return on Equity (ROE) | -30.74% | -33.59% | -10.67% | 3.46% | -89.25% |
| Return on Capital Employed (ROCE) | -31.93% | -34.34% | -22.51% | 3.77% | -69.17% |
| Return on Invested Capital (ROIC) | -31.36% | -33.91% | -22.23% | 2.76% | -63.93% |
| Return on Tangible Assets | -24.26% | -23.52% | -6.92% | 2.08% | -51.85% |
| Earnings Yield | -39.19% | -17.67% | -3.54% | 2.08% | -20.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.08 | 34.82 | 4.92 | 74.44 | 3.67 |
| Payables Turnover | 0.71 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.42 | 3.82 | 3.85 | 4.58 | 1.10 |
| Asset Turnover | 0.25 | 0.40 | 0.37 | 0.46 | 0.03 |
| Working Capital Turnover Ratio | 0.30 | 0.51 | 0.54 | 0.74 | 0.04 |
| Cash Conversion Cycle | -480.79 | 10.48 | 74.19 | 4.90 | 99.44 |
| Days of Sales Outstanding | 30.21 | 10.48 | 74.19 | 4.90 | 99.44 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 511.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 30.21 | 10.48 | 74.19 | 4.90 | 99.44 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.71 | -2.21 | -0.68 | 1.21 | -5.13 |
| Free Cash Flow Per Share | -2.72 | -2.24 | -0.79 | 0.92 | -5.26 |
| Dividend Paid and CapEx Coverage Ratio | -322.92 | -92.20 | -6.24 | 4.14 | -39.65 |
| Capital Expenditure Coverage Ratio | -322.92 | -92.20 | -6.24 | 4.14 | -39.65 |
| Operating Cash Flow Coverage Ratio | -2.97 | -2.09 | -0.60 | 0.34 | -1.95 |
| Operating Cash Flow to Sales Ratio | -1.10 | -0.43 | -0.11 | 0.16 | -10.93 |
| Free Cash Flow Yield | -44.38% | -13.18% | -2.50% | 5.41% | -14.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.55 | -5.66 | -28.24 | 47.97 | -4.78 |
| Price-to-Sales (P/S) Ratio | 2.50 | 3.31 | 5.32 | 2.18 | 78.81 |
| Price-to-Book (P/B) Ratio | 0.78 | 1.90 | 3.01 | 1.66 | 4.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.25 | -7.59 | -39.98 | 18.48 | -7.04 |
| Price-to-Operating Cash Flow Ratio | -2.26 | -7.67 | -46.39 | 14.02 | -7.21 |
| Price-to-Earnings Growth (PEG) Ratio | 0.13 | -0.03 | 0.07 | -0.46 | -0.04 |
| Enterprise Value Multiple | 0.61 | -3.23 | -23.91 | 11.05 | -3.34 |
| Enterprise Value | -38.03M | 249.71M | 577.79M | 151.38M | 672.65M |
| EV to EBITDA | 0.61 | -3.23 | -23.91 | 11.05 | -3.34 |
| EV to Sales | -0.57 | 1.80 | 3.66 | 0.74 | 54.43 |
| EV to Free Cash Flow | 0.51 | -4.13 | -27.51 | 6.24 | -4.86 |
| EV to Operating Cash Flow | 0.51 | -4.18 | -31.92 | 4.73 | -4.98 |
| Tangible Book Value Per Share | 7.81 | 8.93 | 10.46 | 10.22 | 8.67 |
| Shareholders’ Equity Per Share | 7.81 | 8.93 | 10.46 | 10.22 | 8.67 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.07 | 0.12 | 0.00 |
| Revenue Per Share | 2.45 | 5.13 | 5.92 | 7.78 | 0.47 |
| Net Income Per Share | -2.40 | -3.00 | -1.12 | 0.35 | -7.74 |
| Tax Burden | 1.00 | 1.00 | 1.07 | 0.88 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.03 | 0.87 | 1.00 |
| Research & Development to Revenue | 1.67 | 1.41 | 1.22 | 0.72 | 14.06 |
| SG&A to Revenue | 0.69 | 0.38 | 0.34 | 0.22 | 3.35 |
| Stock-Based Compensation to Revenue | 0.38 | 0.27 | 0.22 | 0.15 | 2.34 |
| Income Quality | 1.13 | 0.74 | 0.61 | 3.42 | 0.66 |
Currency in USD
